Policy Forum

The TPP and Pharmaceutical Protections: Too Strong, Too Weak, or Just Right?

Watch the Event
Date and Time
June 16, 2016 12 - 1:30 PM EDT
Hayek Auditorium, Cato Institute

Join the conversation on Twitter using #CatoEvents. Follow @CatoEvents on Twitter to get future event updates, live streams, and videos from the Cato Institute. If you have questions or need assistance registering for the event, please email our staff at events@​cato.​org.

If enacted, the Trans‐​Pacific Partnership will promote economic growth in the United States and 11 other countries in the Asia‐​Pacific region by reducing protectionist trade barriers. The agreement will also set rules in areas other than trade policy, including minimum standards of patent protection in all member countries. These patent rules have led many groups to criticize the TPP and other similar agreements for increasing the cost of drugs in poor countries. Some proponents of the agreement counter by noting the importance of patent protection both for promoting the development of new drugs and for driving growth in high‐​tech industries.

The most controversial pharmaceutical provision in the TPP has been a requirement to provide a greater period of exclusivity to a special class of drugs known as biologics. The U.S. pharmaceutical industry has complained that the TPP’s biologic provision is not strict enough, and powerful members of Congress may prevent the TPP’s ratification unless something can be done to strengthen the rule.

Are the TPP’s patent rules too strong, too weak, or just right? Come hear our expert panel discuss what the TPP will do, or should do, to shape the global pharmaceutical market.

Featuring Joseph Damond, Senior Vice President, Biotechnology Innovation Organization; Burcu Kilic, Legal and Policy Director, Public Citizen Global Access to Medicine Program; and Walter Park, Professor of Economics, American University; moderated by K. William Watson, Trade Policy Analyst, Cato Institute.